Cisplatin is one of the antineoplastic agents most frequentlyused in intraperitoneal chemo-hyperthermia (IPCH) [1–5].The rationale for its use is its potentiation at high temperaturesand its ability to act at any stage of malignant cell replication[1, 6]. However, if this drug has proven activity in the treatment of intraperitoneal malignancies such as gastric and ovarian carcinomas [7–9], no such efficacy has been demonstratedin colorectal or appendix adenocarcinomas.